Poolbeg 和 Hookipa Pharma 正在合并,以建立一个专注于癌症免疫疗法的生物制药公司。 Poolbeg and Hookipa Pharma are merging to create a biopharmaceutical company focused on cancer immunotherapies.

Poolbeg Pharma和Hookipa Pharma正在谈判,以合并成一项全股交易,目的是组建一家Nasdaq上市的生物制药公司。 Poolbeg Pharma and Hookipa Pharma are in talks to merge in an all-share deal, aiming to form a Nasdaq-listed biopharmaceutical company. 合并后的实体将侧重于发展癌症免疫疗法,包括Hookipa的HB-700和Poolebeg的POLB001。 The merged entity would focus on developing immunotherapies for cancer, including Hookipa's HB-700 and Poolbeg's POLB 001. 两家公司还与Gilead Science公司合作开展项目。 Both companies also have partnered programs with Gilead Sciences. Hookipa计划筹集高达3 000万美元的资金,资助联合公司,到2026年,公司将无债务。 Hookipa plans to raise up to $30 million to fund the combined company, which would be debt-free through 2026.